Literature DB >> 10414234

Abnormal levels of proinflammatory cytokines in serum and monocyte cultures from patients with chronic myeloid leukemia in different stages, and their role in prognosis.

M Anand1, S K Chodda, P M Parikh, J S Nadkarni.   

Abstract

Interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), primarily monocyte-derived cytokines, form a group of proinflammatory cytokines with related and overlapping spectra of activities. The role of these cytokines in chronic myeloid leukemia (CML) has been investigated. A distinctive pattern of cytokine secretion has been found in chronic myeloid leukemia in chronic phase (CML-CP), in blastic crisis (CML-BC) and in normal subjects. Serum IL-6 levels in CML-CP and CML-BC were significantly raised compared with normal controls (p = 0.0026 for CML-CP and p = 0.0011 for CML-BC). IL-6 was significantly elevated in blastic crisis of CML (103.5 +/- 20.77 pg ml-1) compared with CML-CP (37.35 +/- 10.88 pg ml-1; p = 0.014). IL-6 serum levels were found to correlate significantly with peripheral blood monocyte counts and bone marrow blast and basophil counts. We have analysed monocyte/macrophage function with respect to their ability to produce IL-1, IL-6 and TNF-alpha, spontaneously as well as in response to LPS, in comparison with normal controls. A direct correlation of IL-6 levels in unstimulated and stimulated cultures with bone marrow blast and basophil counts has been observed. From these results it is inferred that the monocyte function is impaired in CML patients, and the cytokine secretion is deficient. Our limited data suggest that serum IL-6 levels may play an important role as a prognostic marker for CML.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10414234     DOI: 10.1002/(sici)1099-1069(199812)16:4<143::aid-hon628>3.0.co;2-u

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  21 in total

1.  Standardized pretreatment inflammatory laboratory markers and calculated ratios in patients with oral squamous cell carcinoma.

Authors:  Martin Grimm; Johan Rieth; Sebastian Hoefert; Michael Krimmel; Sven Rieth; Peter Teriete; Susanne Kluba; Thorsten Biegner; Adelheid Munz; Siegmar Reinert
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-02-29       Impact factor: 2.503

Review 2.  Pro-inflammatory cytokines: emerging players regulating HSC function in normal and diseased hematopoiesis.

Authors:  Cristina Mirantes; Emmanuelle Passegué; Eric M Pietras
Journal:  Exp Cell Res       Date:  2014-08-19       Impact factor: 3.905

3.  Ubiquitination is not omnipresent in myeloid leukemia.

Authors:  Ramesh C Nayak; Jose A Cancelas
Journal:  Haematologica       Date:  2019-09       Impact factor: 9.941

4.  Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells.

Authors:  Robert S Welner; Giovanni Amabile; Deepak Bararia; Akos Czibere; Henry Yang; Hong Zhang; Lorena Lobo De Figueiredo Pontes; Min Ye; Elena Levantini; Annalisa Di Ruscio; Giovanni Martinelli; Daniel G Tenen
Journal:  Cancer Cell       Date:  2015-05-11       Impact factor: 31.743

5.  Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.

Authors:  Jirí Pavlů; Andrea K Kew; Beatrice Taylor-Roberts; Holger W Auner; David Marin; Eduardo Olavarria; Edward J Kanfer; Donald H MacDonald; Dragana Milojkovic; Amin Rahemtulla; Katayoun Rezvani; John M Goldman; Jane F Apperley; Richard M Szydlo
Journal:  Blood       Date:  2010-03-19       Impact factor: 22.113

6.  IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development.

Authors:  Damien Reynaud; Eric Pietras; Keegan Barry-Holson; Alain Mir; Mikhail Binnewies; Marion Jeanne; Olga Sala-Torra; Jerald P Radich; Emmanuelle Passegué
Journal:  Cancer Cell       Date:  2011-11-15       Impact factor: 31.743

7.  Relationship between lymphocyte to monocyte ratio and brain metastasis in non-smalll cell lung cancer patients.

Authors:  Yafeng Liu; Chunxiao Hu; Jing Wu; Jiawei Zhou; Wenyang Wang; Xueqin Wang; Jianqiang Guo; Qingsen Wang; Xin Zhang; Jun Xie; Yingru Xing; Xuansheng Ding; Dong Hu
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

Review 8.  Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies.

Authors:  John Joson Ng; S Tiong Ong
Journal:  Curr Hematol Malig Rep       Date:  2022-10-19       Impact factor: 4.213

9.  Leptin reverts pro-apoptotic and antiproliferative effects of α-linolenic acids in BCR-ABL positive leukemic cells: involvement of PI3K pathway.

Authors:  Aurore Beaulieu; Géraldine Poncin; Zakia Belaid-Choucair; Chantal Humblet; Gordana Bogdanovic; Georges Lognay; Jacques Boniver; Marie-Paule Defresne
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

10.  Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment.

Authors:  Zuzana Humlová; Hana Klamová; Ivana Janatková; Karin Malíčková; Petra Králíková; Ivan Sterzl; Zdeněk Roth; Eva Hamšíková; Vladimír Vonka
Journal:  Clin Dev Immunol       Date:  2010-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.